Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size.

Trial Profile

Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Octreotide (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jun 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top